Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: Stephen D. Wilson who wrote (44)	2/1/1999 10:19:00 AM
From: campe	Read Replies (1) \| Respond to of 105

Thanks...I think the writer/editor of that article got a few phone calls or something cause it seems that they PULLED the electronic article off the web. I bet their IR/PR spin Dr. sold the TulsaWorld the article as a medical breakthrough. If I were then, I'd be ticked off and do an investigative follow-up article on this breakthrough... tulsaworld.com Its difficult to analyze a company that doesn't disclose publicly through SEC filings. The only information that is known comes from either the company itself of some IR firm hired (or paid in cheap stock). If fact, on their web page it says Morgan-Phillips Inc. has an equity position in the company and may benefit financially as the price of the stock increases. It would be nice to know how much equity was "given" to them and at what equivalent share price. morgan-phillips.com Additionally, the article claimed that there are about 478 safety syringes have either been patented or are in development. What will make Maxxon's unique? Is it strictly because of price/unit? Also, how will they protect their technology? The good Dr. had a sample for the camera, so I assume its a proven design. I would at least look for a patent on it. What's the big company gonna get when they buy Maxxon? A patent? A prototype? Intellectual property? And, how will this relate to shareholders? With 12M shares O/S, they better at least offer $18M just to get the current $1.50 share price. $18M for a patent or prototype of a syringe that is gonna compete with 477 others seems kinda steep. Anyways, I'd be careful with this one. Gifford Mabie (current CEO of MXON) used to run CVIA, until he ran it into the ground with stock dilution (to a family run IR firm) and Reg S. Here's some info on Ron Williams, the guy who did the Reg S for CVIA and Gifford Mabie. Message 5700785 Message 5701151 This is his site. Notice Corporate Vision on his list of accomplishments... selectcapital.com Anyways, don't want to seem negative. I just wish someone warned me about this guy BEFORE I invested in one of his companies.